Article: article from journal or magazin.
Rhumatotogie. Les coxibes augmentent-ils les risques cardiovasculaires [Rheumatology. Do coxibs pose a cardiovascular risk?]
Revue Médicale Suisse
There is ongoing controversy regarding the cardiovascular safety of coxibes. Inhibition of COX-2 may have a pro-coagulant effect though available data does not support a class effect in human use. In clinical practice, prudence with its prescription is recommended. In cases which require treatment beyond one week, the individual cardiovascular and gastrointestinal risks need to be assessed. If the risk is predominantly gastrointestinal, a COXIB is indicated. If the cardiovascular risk is major, then a classical NSAID with gastric protection may be more appropriate.
Cardiovascular Diseases, Cyclooxygenase Inhibitors, Humans, Risk Factors
Last modification date